



Crea, F., Bairey Merz, C. N., Beltrame, J. F., Berry, C., Camici, P. G., Kaski, J. C., Ong, P., Pepine, C. J., Sechtem, U. and Shimokawa, H. (2019) Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. *European Heart Journal*, 40(29), pp. 2455-2462. (doi:[10.1093/eurheartj/ehy857](https://doi.org/10.1093/eurheartj/ehy857)).

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/192675/>

Deposited on: 24 January 2020

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

European Heart Journal

Mechanisms and Diagnostic Evaluation of Persistent or Recurrent Angina following Percutaneous Coronary Revascularisation --Manuscript Draft--

Manuscript Number:	EURHEARTJ-D-18-01713R4
Full Title:	Mechanisms and Diagnostic Evaluation of Persistent or Recurrent Angina following Percutaneous Coronary Revascularisation
Article Type:	Clinical review (Unsolicited)
Keywords:	Coronary microvascular dysfunction, Coronary spasm, Coronary stenosis, Percutaneous coronary intervention, Stable angina
Corresponding Author:	Filippo Crea, MD, FESC Universita Catolica del Santo Cuore Roma, ITALY
Order of Authors (with Contributor Roles):	Filippo Crea, MD Noel Bairey Merz Beltrame BELTRAME Colin Berry Paolo CAMICI Juan Carlos Kaski Peter Ong Carl Pepine Udo Sechtem Hiro Shimokawa
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Universita Catolica del Santo Cuore
Corresponding Author's Secondary Institution:	
First Author:	Filippo Crea, MD
Order of Authors Secondary Information:	
Abstract:	<p>Abstract</p> <p>Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect up to 20-40% of patients at 1-year follow up. This appears to be true even when PCI is "optimised" using physiology-guided approaches and drug-eluting stents. Importantly, persistent or recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be almost 2-fold higher among patients with persistent or recurrent angina post-PCI versus those who become symptom-free. However, practice guideline recommendations regarding the management of patients with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina are relevant, and more research seems warranted. The purpose of this document is to review potential mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic algorithm and summarize current knowledge gaps.</p>
Suggested Reviewers:	
Opposed Reviewers:	
Additional Information:	

Question	Response
TWITTER message (Please submit a catchy Twitter message of max. 140 characters, which we would use to promote this submission in the event of acceptance - Max 140 characters).	Angina recurs or persists after PCI in about one third of patients. We provides information on mechanisms, diagnosis and knowledge gaps
Word Count Manuscript-only (excluding references):	6659
Total Word Count:	6659
Section/Category Name	3. Controversies in Cardiovascular Medicine
Did you cite ESC guidelines where appropriate?	yes
As Corresponding Author, I take full responsibility for all information declared in this notification.	Yes
As Corresponding Author, I agree to be the principal correspondent with the Editorial Office, review the edited manuscript and proof, and make decisions about releasing manuscript information to the media, federal agencies, etc.	Yes
All persons named in the Acknowledgements Section have provided the Corresponding Author with written permission to be named in the manuscript.	Yes
All persons who have made substantial contributions to the manuscript (e.g. data acquisition, analysis, or writing / editing assistance), but who do not fulfill authorship criteria, are named with their specific contributions in the Acknowledgements Section of the manuscript.	Yes
If an Acknowledgements Section is not included in the paper then no other persons have made substantial contributions to this manuscript.	Yes
Please enter the names of the authors who <i>Performed statistical analysis</i>	No statistical analysis needed
Please enter the names of the authors who <i>Acquired the data</i>	All
Please enter the names of the authors who <i>Conceived and designed the research</i>	Filippo Crea

Please enter the names of the authors who <i>Drafted the manuscript</i>	Filippo Crea
Please enter the names of the authors who <i>Made critical revision of the manuscript for key intellectual content</i>	All
Please enter the names of the authors who did anything else on the manuscript other than what we have listed:	Nobody
This manuscript represents valid and substantiated work.	Yes
If asked, I will provide or fully cooperate in obtaining and providing the original data on which the manuscript is based so the editors or their designates can examine it.	Yes
The paper under question is being submitted by an ESC Working Group.	No
Each person listed as co-author has been entered as contributing to at least one part of the manuscript	Yes
TWITTER message (Please submit a catchy Twitter message of max. 280 characters, which we would use to promote this submission in the event of acceptance - Max 280 characters).	Persistent or recurrent angina after PCI is a relevant clinical problem not satisfactorily addressed by current Guidelines. This article provides information on mechanisms of persistent or recurrent angina after PCI as well as clinical guidance in this setting.
First Author Secondary Information:	

Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularisation

Short title: Diagnostic evaluation of post-PCI angina

Filippo Crea¹ MD;

C. Noel Bairey Merz² MD;

John F Beltrame³ BSc, BMBS, PhD;

Colin Berry⁴ PhD FRCP;

Paolo G Camici⁵ MD; FRCP

Juan Carlos Kaski⁶ DSc, MD;

Peter Ong⁷ MD;

Carl J. Pepine MD⁸;

Udo Sechtem⁷ MD;

Hiroaki Shimokawa⁹ MD, PhD;

On behalf of the Coronary Vasomotion Disorders International Study Group (COVADIS)

Word count 6670

INSTITUTIONAL AFFILIATIONS:

1. F. Policlinico Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
2. Barbra Streisand Women's Heart Center, Smidt Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
3. University of Adelaide, Basil Hetzel Institute, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
4. British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, UK.
5. Vita Salute University and San Raffaele Hospital, Milan, Italy.
6. Cardiovascular and Cell Sciences Research Institute, St George's, University of London, London, UK.
7. Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
8. Division of Cardiovascular Medicine, University of Florida, Gainesville Florida, USA.
9. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

CORRESPONDENCE ADDRESS:

Filippo Crea, MD
Professor of Cardiology
Director, Department of Cardiovascular and Thoracic Sciences
Fondazione Policlinico A. Gemelli
Università Cattolica del Sacro Cuore
L.go Vito 1, 00168 Roma
Tel: +39/06/3051166
Fax: +39/06/3055535
E-mail: filippo.crea@unicatt.it

Abstract

1
2 Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect about
3
4 20-40% of patients during short-medium term follow-up. This appears to be true even when PCI is
5
6 “optimised” using physiology-guided approaches and drug-eluting stents. Importantly, persistent or
7
8 recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be
9
10 almost 2-fold higher among patients with persistent or recurrent angina post-PCI versus those who
11
12 become symptom-free. However, practice guideline recommendations regarding the management of
13
14 patients with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina
15
16 are relevant, and more research seems warranted. The purpose of this document is to review potential
17
18 mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic
19
20 algorithm and summarize current knowledge gaps.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1
2 Procedural success is routinely achieved in patients with obstructive coronary artery disease
3
4 (CAD) undergoing percutaneous coronary intervention (PCI). In the current European Society of
5
6 Cardiology guidelines on stable obstructive CAD, coronary revascularisation has a Class 1, Level A
7
8 recommendation on prognostic grounds for patients with left main stem disease or multivessel CAD,
9
10 and also for symptoms in the presence of limiting angina or angina-equivalent, unresponsive to
11
12 optimal medical therapy (1). Persistence or recurrence of angina after PCI is well recognised and may
13
14 affect about 20-40% of patients during short-medium term follow-up (2-7). This appears to be true
15
16 even when PCI is “optimised” using physiology-guided approaches [e.g. fractional-flow reserve
17
18 (FFR) or non-hyperaemic pressure ratio (NHPR)] (8) and drug-eluting stents (DES) or stents with
19
20 bioresorbable scaffolds (9). Importantly, persistent or recurrent angina post-PCI is associated with a
21
22 significant economic burden. Healthcare costs may be almost 2-fold higher among patients with
23
24 persistent or recurrent angina post-PCI versus those who become symptom-free (10). Furthermore,
25
26 the role of PCI for symptom relief, when added to optimal medical therapy, remains a controversial
27
28 issue (11-14). In the ORBITA trial, the benefits of PCI compared to a “sham control” placebo were
29
30 unclear. One potential mechanism for persistent angina post-PCI identified by the investigators was
31
32 microvascular angina (2), although this trial has been criticised because of methodological limitations
33
34 (15).

35
36
37
38
39
40
41
42
43 The clinical importance of angina recurrence following successful PCI is evident from
44
45 developments in clinical quality registries, where post-PCI angina is being utilized as a clinical
46
47 performance marker for PCI (16). Despite this, while prospective studies have documented that
48
49 angina, including with inducible ischaemia, is a contributing factor in many patients with chest
50
51 discomfort symptoms post-PCI (17), few studies have systematically addressed the mechanisms
52
53 responsible for the recurrent angina (18,19) and there are no comprehensive recommendations for its
54
55 diagnosis or treatment (1,20).

1 The purpose of this document, which expands and gives a global perspective to what we have
2 previously published (3), is to review potential mechanisms for the persistence or recurrence of
3
4 angina post-PCI, propose a practical diagnostic algorithm, and summarize current knowledge gaps.
5
6
7
8

9 **Mechanisms of persistent or recurrent angina after PCI**

10
11 Elective PCI in patients with stable angina is routinely successful and procedure-related
12
13 problems are uncommon. Procedural success reflects effective education and training, the
14
15 availability of state-of-the-art stent technologies, use of adjunctive intravascular imaging and
16
17 physiology techniques, and quality assurance (21).
18
19
20

21
22 Despite procedural success, angina may persist or recur in a large proportion of patients,
23
24 which is frustrating for patients and clinicians. In contemporary practice, clinicians are focused on
25
26 identifying a “flow-limiting” stenosis amenable to PCI with stents when sometimes other potential
27
28 causes are relevant. This issue could be considered as ‘detection bias’.
29
30

31
32 Yet, the pathophysiology of persisting or recurring angina after successful PCI is
33
34 heterogeneous. Aside from non-cardiac causes of angina, structural and functional alterations in the
35
36 coronary circulation may be implicated (Table 1 and Figure 1).
37
38
39
40

41 *Flow limiting epicardial obstructions*

42
43 Stent thrombosis and in-stent restenosis are infrequent causes of recurrent angina and
44
45 ischaemia after PCI in contemporary clinical practice with rates of stent thrombosis <1% at 1-year
46
47 and 0.2-0.4% per year thereafter, and rates of clinically relevant in-stent restenosis of 5% at 1-year
48
49 follow-up (22). Recurrence rate of major adverse cardiac events due native vessel disease progression
50
51 is < 5% at 1-year follow up (23), although disease progression and cardiac events are higher in
52
53 patients with diabetes (24).
54
55
56
57

58
59 Persistence of angina caused by incomplete coronary may occur in up to 30% in the current
60
61 era, although definitions of incomplete revascularisation are heterogeneous (25).
62
63
64
65

1
2 Other potential causes of angina post-PCI include diffuse atherosclerosis without a focal
3 stenosis leading in turn to an insidious pressure gradient along the length of the coronary artery,
4 coronary dissection, myocardial bridging and thromboembolism, all of which may have been
5 overlooked during the index procedure.
6
7
8
9

10
11 *Coronary vasomotion disorders of epicardial arteries and microcirculation*
12
13

14 Functional causes of persistent or recurrent angina following a technically successful PCI
15 include vasomotion disorders of epicardial coronary arteries, as well as coronary microvascular
16 dysfunction (CMD). Accordingly, current European Society of Cardiology guidelines on stable CAD
17 have acknowledged the role of coronary vascular dysfunction in causing angina post-PCI (1). If
18 vasomotor function has not been specifically assessed in a patient with angina before undergoing PCI,
19 it is impossible to know the time-course of these functional alterations. Of note, stent implantation
20 may cause or enhance coronary vascular dysfunction increasing the propensity of epicardial coronary
21 vasospasm and/or CMD. Overall, these functional mechanisms may be causally implicated in about
22 half of patients with angina post-PCI although, again, prospective studies are lacking (3).
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Significant constriction of epicardial coronary arteries at or distal to the PCI site is a potential
37 cause of recurrent angina (26). Ong *et al.* (27) documented epicardial spasm (>75% narrowing),
38 associated with reproduction of patient's symptoms, in response to intracoronary acetylcholine (ACh)
39 at increasing doses; up to 200 µg for the left coronary artery or with 80 µg for the right coronary
40 artery (Figure 2). Significant constriction occurred in about half of the patients undergoing coronary
41 angiography for post-PCI recurrent angina without haemodynamically significant coronary stenoses.
42
43
44
45
46
47
48
49
50
51 These observations support a mechanistic role for epicardial coronary artery constriction in patients
52 with angina persistence or recurrence post-PCI. Heightened activation of the Rho-kinase pathway, a
53 central molecular mechanism for vascular smooth muscle constriction, might also be involved in the
54 pathogenesis of DES-related enhanced epicardial artery constriction (28).
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

CMD in post-PCI angina, type-3 by the classification of Camici and Crea (29), can be caused by impaired microvascular dilation resulting in a reduction of coronary flow reserve, similar to that caused by an epicardial stenosis, or by microvascular spasm (Figure 2). In a study of patients with post-PCI recurrent angina compared to matched patients without angina post-PCI, Li et al. (30) observed a more profound reduction in coronary blood flow (CBF) in association with an increase in the index of microvascular resistance (IMR) in response to intravenous adenosine (140 µg/kg/min). The impairment of hyperaemic CBF and increase in IMR was even more relevant in those with abnormal exercise stress test (EST) result and persisted at 6- and 12-month follow-up. These findings are consistent with studies using transthoracic Doppler echocardiography by Milo et al. (31). In their study, hyperaemic coronary artery blood flow velocity in the left anterior descending (LAD) was impaired at 1-day, 3- and 6-months after successful PCI compared to controls. Importantly, similar impairment of the CBF response to cold pressor testing was also observed, suggesting impaired endothelium-dependent vasodilator function of the coronary microcirculation. Furthermore, a greater impairment of the CBF response predicted restenosis in the LAD coronary artery during long-term follow-up (32). Among patients who underwent PCI with second-generation DES, Hokimoto et al. (33) found impaired CBF response to both ACh (an endothelium-dependent stimulus) and adenosine (mostly an endothelium-independent stimulus). Overall, in this study, evidence of CMD was evident in 59% of patients with previous PCI. Finally, Ong et al. suggested coronary microvascular spasm might contribute to post-PCI recurrent angina in approximately 1 in 5 affected patients (27). Specifically, following intra-coronary infusion of acetylcholine, affected patients experienced angina and ischaemic ECG changes without evident epicardial constriction, suggesting microvascular spasm rather than epicardial constriction was causal for the angina.

53
54
55
56
57
58
59
60
61
62
63
64
65

Mechanisms underlying CMD post-PCI are poorly understood, heterogeneous, and potentially more than one problem may be operative in any given patient (34). First, chronic coronary microcirculation adaptation to reduced perfusion pressure distal to a stenosis or to an occlusion would be expected to negatively influence microvascular remodelling and its capacity to maximally dilate

1 after restoration of a more physiologic perfusion pressure. Furthermore, the time required for the
2 coronary microcirculation to recover to baseline vasomotor reactivity is likely to be variable between
3 patients (35).
4
5

6
7 Second, PCI might contribute to CMD by causing microembolisation of debris material,
8 which may obstruct small coronary arteries, arterioles and/or capillaries to cause perivascular
9 inflammation and even capillary obliteration and cardiomyocyte injury (36). Furthermore, the DES
10 per se causes vasoconstriction in the adjacent and downstream coronary macro- and microcirculation,
11 potentially due to elution of the active drug and polymer constituents downstream. Although these
12 detrimental effects of DES might be mediated by endothelial dysfunction (37), more recent studies
13 suggest that they are mainly mediated by activation of Rho-kinase in smooth muscle cells and,
14 accordingly, are prevented by Rho-kinase inhibitors (38,39).
15
16
17
18
19
20
21
22
23
24
25

26 Third, CMD may have pre-dated the index PCI procedure which was “unmasked” when the
27 epicardial obstruction was relieved by PCI. In particular, CMD with microvascular rarefaction is
28 implicated in heart failure with preserved ejection fraction (40,41).
29
30
31
32
33

34 Last but not least, coronary microcirculation regulates myocardial blood flow, and therefore
35 shear stress in large epicardial arteries which in turn directs vessel remodelling and plaque formation.
36
37
38
39
40

41 **Diagnostic evaluation of persistent or recurrent angina after PCI**

42 *Non-invasive diagnostic tests*

43
44
45
46 European Society of Cardiology guidelines for stable obstructive CAD recommend a stress
47 test at follow-up in patients with persistent or recurrent angina post-PCI, preferably a stress test that
48 is combined with imaging (Class I, level of evidence C) (1). Thus, non-invasive stress tests represent,
49 in most cases, the first diagnostic assessment for patients presenting with angina post-PCI.
50
51
52
53
54
55

56 ECG stress testing in the diagnostic and prognostic assessment of patients with stable
57 ischaemic heart disease is well established as it helps guide the initial treatment strategy (1). The
58 diagnostic performance of CTCA for the evaluation of in-stent restenosis is generally lower than in a
59
60
61
62
63
64
65

1 native vessel, and adjunctive estimation of fractional flow reserve (FFR-CT) in a vessel with a stent
2 is relatively contra-indicated (42). The role of ECG stress testing alone after PCI is debated because
3
4 the positive predictive value for obstructive stenosis/restenosis is only moderately high (43). A key
5
6 issue is that an abnormal ECG stress test can be caused by both obstructive CAD and functional
7
8 mechanisms (CMD, epicardial vasoconstriction, etc.). In both clinical scenarios, evidence of
9
10 exertional angina and ECG abnormalities consistent with ischaemia provide objective evidence that
11
12 should be useful for onward management.
13
14
15

16
17 Similar considerations apply to stress myocardial perfusion imaging by single photon
18
19 emission tomography (SPECT). Positron emission tomography (PET) is a well-validated technique
20
21 that provides non-invasive, accurate, and reproducible quantification of both global and regional
22
23 myocardial blood flow (MBF; ml/g/min) and coronary flow reserve (CFR). Clinical research using
24
25 PET has provided substantial new knowledge on CMD in various clinical settings. Indeed, evidence
26
27 of segmental abnormalities more often implicates an epicardial problem while CMD is associated
28
29 with a global reduction of CFR (44,45). Recent studies suggest that cardiac magnetic resonance may
30
31 discriminate between epicardial and microvascular causes of myocardial ischaemia (46,47).
32
33
34
35

36 Stress echocardiography (with either exercise or pharmacological stressor) may be useful to
37
38 distinguish between epicardial and microvascular coronary mechanisms. Indeed, a dissociation
39
40 between angina and ischemic ST segment changes on the one hand and lack of regional wall motion
41
42 abnormalities on the other hand, is a typical feature of microvascular angina due to the patchy
43
44 distribution of ischemia in this setting (48-51). In sharp contrast, as established in the ischemic
45
46 cascade concept where regional wall motion abnormalities precede electrical abnormalities
47
48 and both precede symptoms, it is very unlikely for patients with epicardial coronary stenoses
49
50 to experience angina and ischemic ST segment changes in the absence of regional wall motion
51
52 abnormalities (48).
53
54
55
56
57
58
59
60

61 *Invasive diagnostic tests*

62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Current European Society of Cardiology guidelines on stable CAD recommend invasive coronary angiography in clinically stable patients with high-risk ischaemic findings (>10% of myocardium) at stress imaging (Class I, level of evidence C) (1). However, the threshold for coronary angiography might be lower after high risk PCI (Class IIb, level of evidence C) (1). Considering the limited negative predictive value of a non-invasive test, then an invasive approach may be chosen independent of non-invasive test results, particularly when the history is strongly supporting angina recurrence because it offers the opportunity to test both structural and functional alterations of coronary circulation (Figure 3). Multi-territory ischaemia (both transmural and regional) may not be detected by non-invasive tests (3). Moreover, patients with persistent or recurrent angina and incomplete revascularisation need to be reassessed if additional revascularisation is considered to be technically feasible. Finally, in case of an intermediate stenosis on coronary angiography, FFR or NHPR measurements can be helpful to confirm the presence of a haemodynamically significant epicardial stenosis. However, the caveat is that in the presence of CMD, it may be unclear whether near maximal hyperaemia is achieved, thus limiting the usefulness of FFR measurements without measuring CFR or indices of myocardial resistance (52).

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
A second indication for coronary angiography is the occurrence of angina at rest, despite optimal medical treatment and negative non-invasive testing. This scenario should strongly suggest functional coronary alterations. In this patient subset, invasive coronary angiography might sometimes establish the presence of subcritical unstable coronary plaques, which can be further investigated by intravascular imaging (OCT, IVUS, etc.). In the absence of subcritical unstable plaques, the assessment of epicardial and microvascular coronary vasomotion may reveal functional causes of persistent angina. In both scenarios, invasive coronary angiography is necessary to elucidate the causes of angina.

55
56
57
58
59
60
61
62
63
64
65
Coronary artery vasomotion is mainly assessed invasively, usually by intracoronary administration of drugs, such as ACh or ergonovine (1,3). The safety of intracoronary provocative testing has been convincingly proven in previous studies (53). Some have advocated non-invasive

1 assessments using ergonovine stress echocardiography in patients known to have non-obstructive
2 CAD (54). Coronary vasomotion in response to acetylcholine reflects the interplay between
3
4 endothelial and smooth muscle cell responses. Acetylcholine elicits endothelium-dependent
5
6 vasodilatation when the endothelium is functional, but in pathological conditions, characterised by
7
8 endothelial dysfunction and/or smooth muscle cell hyperreactivity, it may result in no dilatation or
9
10 even trigger vasoconstriction or spasm via stimulation of smooth muscle cell muscarinic receptors.
11
12 Ergonovine acts primarily via serotonergic receptors on vascular smooth muscle cells but also on
13
14 α -adrenergic and dopaminergic receptors, unmasking predisposition to vasoconstriction or spasm.
15
16 ACh is preferred because it is relatively short-acting, specific in its selectivity for muscarinic
17
18 receptors and the intracoronary dosing is devoid of systemic effect; whereas ergonovine effects
19
20 multiple receptors, is longer acting and even with intracoronary dosing may have some systemic
21
22 effects (blood pressure increases). Nevertheless, at present, it is unclear whether ACh or ergonovine
23
24 is superior to detect spasm in patients with persisting angina post-PCI also because they might
25
26 identify different subsets of patients with vasospastic angina (55).
27
28
29
30
31
32
33

34 Coronary artery spasm is defined as a transient (e.g. reversible) coronary artery occlusion/sub
35
36 occlusion (> 90% narrowing) with signs (ST changes) and symptoms of myocardial ischaemia
37
38 (56,57). Spasm may involve discrete coronary segments in one or multiple arteries, or can be diffuse
39
40 and, when it involves distal coronary vessels, can be suspected to also extend into the
41
42 microvasculature (56).
43
44
45

46 Lack of epicardial coronary spasm by angiography in the presence of ischaemic ECG changes
47
48 and angina suggests microvascular spasm (58). When epicardial spasm occurs, objective
49
50 determination of concomitant microvascular spasm is difficult.
51
52
53

54 Coronary reactivity testing is only performed in a limited number of cardiac catheterization
55
56 laboratories worldwide. The reasons for the low adoption of coronary reactivity testing are
57
58 multifactorial and include lack of evidence from randomised controlled trials, and lack of education
59
60 and training in who to administer the tests. The European Society of Cardiology (ESC) and the
61
62
63
64
65

1 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines make spasm
2 provocation testing only Class IIa and Class IIb, respectively (1,20). However, the Japanese
3
4 Circulation Society and the Coronary Vasomotion Disorders International Study Group (COVADIS)
5
6
7 have recommended routine testing in selected patients (56-58).
8

9 CFR and microvascular resistance can be measured using a pressure- and flow-sensitive
10
11 Doppler catheter or a thermodilution guidewire. These techniques can be performed during coronary
12
13 angiography enabling a comprehensive assessment of CMD by assessing microvascular dilatory
14
15 function (59,60), which may complement coronary reactivity testing within the same procedure.
16
17

18 The Coronary Microvascular Angina clinical trial (CorMicA) is the first to prove the
19
20 diagnostic, health and economic value of an interventional diagnostic procedure, which combines a
21
22 guidewire and coronary vasoreactivity testing, to inform the diagnosis and treatment of patients with
23
24 angina and no obstructive CAD, where the primary outcome is Seattle Angina Score at 6 months (61).
25
26
27
28
29
30

31 *Diagnostic flow chart*

32
33 We recognise that randomised controlled trials for management of post-PCI angina are
34
35 lacking. Nonetheless, given the clinical necessity, practice guidelines are needed. Although symptom
36
37 assessment is important, it is frequently insufficient to establish the cause of persistent or recurrent
38
39 angina after PCI, the only distinctive feature of vasospastic angina being angina at rest, frequently
40
41 nocturnal, with preserved effort tolerance (62) and the only distinctive feature of microvascular
42
43 angina being prolonged chest pain not immediately responsive to nitrates (63). We propose a
44
45 diagnostic algorithm that may assist in the evaluation of patients in this setting (Figure 4). The
46
47 rationale prioritises a person-centred approach with diagnostic tests according to local availability
48
49 and onward management, including coronary angiography, as appropriate. A non-invasive
50
51 assessment will be sufficient in some patients, but in many cases, invasive management including to
52
53 assess coronary vascular function will be needed.
54
55
56
57
58
59
60
61
62
63
64
65

Knowledge gaps

1
2 Patients with persistent or recurrent angina post-PCI present an unmet clinical need. Recent
3
4 studies suggest that PCI may not be relied upon to improve angina (2). The large International Study
5
6 of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical
7
8 trial is assessing the benefits of revascularisation in addition to OMT to improve health outcomes
9
10 (64). A recent study demonstrated that a simple non-invasive assessment of peripheral artery
11
12 endothelial function during index PCI admission predicted the persistence or recurrence of
13
14 angina/ischaemia at follow-up (65), suggesting that assessment of endothelial dysfunction (66) may
15
16 be useful for prediction of structural treatment benefit. We recognise that such tests are not feasible
17
18 in daily practice, but the implication is that treatments which improve endothelial dysfunction may
19
20 be beneficial. This possibility merits further prospective research.
21
22
23
24
25

26 In clinical practice, PCI for stable angina patients is currently a “one-size-fits-all” approach,
27
28 potentially useful for symptom relief in some symptomatic patients found to have epicardial
29
30 obstructive CAD. In other patients, a significant epicardial stenosis may reflect more extensive
31
32 vascular dysfunction, where PCI alone may be ineffective. We think more research is warranted into
33
34 the prevalence and clinical significance of coronary vascular dysfunction in patients undergoing PCI.
35
36
37

38 When obstructive CAD is ruled out, post-PCI angina may be due to coronary vascular dysfunction
39
40 caused by either increased IMR, epicardial or microvascular spasm, or both. In these circumstances,
41
42 repeat PCI would be unlikely to be beneficial. An important knowledge gap is treatment of CMD
43
44 (67). Importantly, early evidence suggests that an empirical treatment of angina in the absence of
45
46 obstructive coronary atherosclerosis guided by the assessment of functional coronary alterations is
47
48 associated to a better outcome as compared to a strategy guided by angiography only (61).
49
50
51
52

53 Finally, while current guidelines on percutaneous coronary revascularization do not fully address
54
55 the issue of persistent/recurrent angina, it would be desirable to do so in the future (68).
56
57
58
59
60
61
62
63
64
65

References

1. Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013;**34**:2949-3003.
2. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet*. 2018;**391**:31-40.
3. Niccoli G, Montone RA, Lanza GA, Crea F. Angina after percutaneous coronary intervention: The need for precision medicine. *Int J Cardiol*. 2017;**248**:14-19.
4. Venkitachalam L, Kip KE, Mulukutla SR, Selzer F, Laskey W, Slater J, Cohen HA, Wilensky RL, Williams DO, Marroquin OC, Sutton-Tyrrell K, Bunker CH, Kelsey SF; NHLBI-Sponsored Dynamic Registry Investigators. Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry. *Circ Cardiovasc Qual Outcomes*. 2009;**2**:607–615.
5. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, Nijjer S, Petraco R, Davies J, Keeble T, Tang K, Malik IS, Cook C, Ahmad Y, Sharp ASP, Gerber R, Baker C, Kaprielian R, Talwar S, Assomull R, Cole G, Keenan NG, Kanaganayagam G, Sehmi J, Wensel R, Harrell FE, Mayet J, Thom SA, Davies JE, Francis DP. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. *Circulation*. 2018;**138**:1780-1792.
6. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkowitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. *N Engl J Med.* 2008;**359**:677-687.
7. Gaglia MA Jr, Torguson R, Lipinski MJ, Gai J, Koifman E, Kiramijyan S, Negi S, Rogers T, Steinvil A, Suddath WO, Satler LF, Pichard AD, Waksman R. Frequency of angina pectoris after percutaneous coronary intervention and the effect of metallic stent type. *Am J Cardiol.* 2016;**117**:526-531.
8. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med.* 2009;**360**:213-224.
9. Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J Jr, Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Généreux P, Kereiakes DJ; ABSORB IV Investigators. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. *Lancet.* 2018 Sep 24. pii:S0140-6736(18)32283-9. doi:10.1016/S0140-6736(18)32283-9. [Epub ahead of print].
10. Ben-Yehuda O, Kazi DS, Bonafede M, Wade SW, Machacz SF, Stephens LA, Hlatky MA, Hernandez JB. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database. *Catheter Cardiovasc Interv.* 2016;**88**:1017-1024.
11. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007;**356**:1503-1516.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
12. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Siletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ*. 2014;348:g3859.doi:10.1136/bmj.g3859.
 13. Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischaemia: a collaborative meta-analysis of contemporary randomized clinical trials. *JAMA Intern Med* 2014;**174**:232-240.
 14. Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr, Harrington RA, Maron DJ. Medical therapy with versus without revascularization in stable patients with moderate and severe ischaemia: the case for community equipoise. *J Am Coll Cardiol*. 2016;**67**:81-99.
 15. Chaitman BR, Mori Brooks M, Fox K, Lüscher TF. ORBITA revisited: what it really means and what it does not? *Eur Heart J*. 2018;**39**:963-965.
 16. Beltrame JF. Post-percutaneous coronary intervention angina in stable coronary artery disease. *Eur Heart J Qual Care Clin Outcomes*. 2016;**2**:66-68.
 17. Radico F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Jespersen L, Chang SM, Humphries KH, Marzilli M, De Caterina R. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. *Eur Heart J*. 2018;**39**:2135-2146.
 18. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Delayed recovery of coronary resistive vessel function after coronary angioplasty. *J Am Coll Cardiol*. 1993;**21**:612-621.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
19. Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Goto T, Kato A, Shinozaki T, Ishida E, Miyata S, Yasuda S, Shimokawa H; NOVEL Investigators. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study. *Eur Heart J*. 2016;**37**:2713-2721.
 20. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2014;**130**:1749-1767.
 21. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet*. 2007;**370**:937-948.
 22. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. *Eur Heart J* 2015;**36**:3320-3331.
 23. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011;**364**:226-235.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
24. Tousek P, Pavei A, Oreglia J, Martin G, Sharif F, Fajadet J, Farah B. Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era. *EuroIntervention* 2009;**4**:588-592.
 25. Gossel M, Faxon DP, Bell MR, Holmes DR, Gersh BJ. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease. *Circ Cardiovasc Interv.* 2012;**5**:597-604.
 26. Gregorini L, Fajadet J, Robert G, Cassagneau B, Bernis M, Marco J. Coronary vasoconstriction after percutaneous transluminal coronary angioplasty is attenuated by antiadrenergic agents. *Circulation.* 1994;**90**:895-907.
 27. Ong P, Athanasiadis A, Perne A, Mahrholdt H, Schäufele T, Hill S, Sechtem U. Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. *Clin Res Cardiol.* 2014;**103**:11-19.
 28. Shimokawa H. 2014 Williams Harvey Lecture: Importance of coronary vasomotion abnormalities-from bench to bedside. *Eur Heart J* 2014;**35**:3180-3193.
 29. Camici PG, Crea F. Coronary microvascular dysfunction. *N Engl J Med.* 2007;**356**:830-40.
 30. Li Y, Yang D, Lu L, Wu D, Yao J, Hu X, Long M, Luo C, Du Z. Thermodilutional confirmation of coronary microvascular dysfunction in patients with recurrent angina after successful percutaneous coronary intervention. *Can J Cardiol.* 2015;**31**:989-997.
 31. Milo M, Nerla R, Tarzia P, Infusino F, Battipaglia I, Sestito A, Lanza GA, Crea F. Coronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress test results. *Int J Cardiol.* 2013;**168**:121-125.
 32. De Vita A, Milo M, Sestito A, Lamendola P, Lanza GA, Crea F. Association of coronary microvascular dysfunction with restenosis of left anterior descending coronary artery disease treated by percutaneous intervention. *Int J Cardiol.* 2016;**219**:322-325.
 33. Hokimoto S, Tabata N, Yamanaga K, Sueta D, Akasaka T, Tsujita K, Sakamoto K, Yamamoto E, Yamamuro M, Izumiya Y, Kaikita K, Kojima S, Matsui K, Ogawa H. Prevalence of

- 1 coronary macro- and micro-vascular dysfunctions after drug-eluting stent implantation
2 without in-stent restenosis. *Int J Cardiol.* 2016;**222**:185-194.
- 3
4
5 34. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. *Eur*
6
7 *Heart J.* 2014;**35**:1101-1111.
- 8
9
10 35. Galassi AR, Tomasello SD, Crea F, Costanzo L, Campisano MB, Marzá F, Tamburino C.
11
12 Transient impairment of vasomotion function after successful chronic totalocclusion
13
14 recanalization. *J Am Coll Cardiol.* 2012;**59**:711-718.
- 15
16
17 36. Selvanayagam JB, Cheng AS, Jerosch-Herold M, Rahimi K, Porto I, van Gaal W, Channon
18
19 KM, Neubauer S, Banning AP. Effect of distal embolization on myocardial perfusion reserve
20
21 after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study.
22
23 *Circulation.* 2007;**116**:1458-1464.
- 24
25
26 37. Gori T, Münzel T. Endothelial dysfunction after stenting and scaffolding of coronary arteries.
27
28 *Clin Hemorheol Microcirc.* 2014;**58**:175-181.
- 29
30
31 38. Aizawa K, Yasuda S, Takahashi J, Takii T, Kikuchi Y, Tsuburaya R, Ito Y, Ito K, Nakayama
32
33 M, Takeda M, Shimokawa H. Involvement of rho-kinase activation in the pathogenesis of
34
35 coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary
36
37 artery disease. *Circ J.* 2012;**76**:2552-2560.
- 38
39
40 39. Tsuburaya R, Yasuda S, Shiroto T, Ito Y, Gao JY, Aizawa K, Kikuchi Y, Ito K, Takahashi J,
41
42
43 Ishibashi-Ueda H, Shimokawa H. Long-term treatment with nifedipine suppresses coronary
44
45 hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in
46
47 pigs in vivo: possible involvement of Rho-kinase pathway. *Eur Heart J.* 2012;**33**:791-799.
- 48
49
50 40. Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa
51
52 H, Camici PG; Coronary Vasomotion Disorders International Study Group (COVADIS). The
53
54 parallel tales of microvascular angina and heart failure with preserved ejection fraction: a
55
56 paradigm shift. *Eur Heart J.* 2017;**38**:473-477.
- 57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
41. Nelson MD, Szczepaniak LS, Wei J, Haftabaradaren A, Bharadwaj M, Sharif B, Mehta P, Zhang X, Thomson LE, Berman DS, Li D, Bairey Merz CN. Diastolic dysfunction in women with signs and symptoms of ischemia in the absence of obstructive coronary artery disease: a hypothesis-generating study. *Circ Cardiovasc Imaging*. 2014;**7**:510-516.
 42. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernández-Golfín C, Rincón LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Mäki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. *Circ Cardiovasc Imaging*. 2015;**8**. pii: e002179. doi:10.1161/CIRCIMAGING.114.002179.
 43. Henderson RA, O'Flynn N; Guideline Development Group. Management of stable angina: summary of NICE guidance. *Heart*. 2012;**98**:500-507.
 44. Camici PG, d'Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. *Nat Rev Cardiol*. 2015;**12**:48-62.
 45. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, Blankstein R, Rimoldi O, Camici PG, Di Carli MF. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. *Circulation*. 2014;**129**:2518-2527.
 46. Thomson LE, Wei J, Agarwal M, Haft-Baradaran A, Shufelt C, Mehta PK, Gill EB, Johnson BD, Kenkre T, Handberg EM, Li D, Sharif B, Berman DS, Petersen JW, Pepine CJ, Bairey Merz CN. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. *A National Heart, Lung, and Blood*

- Institute-sponsored study from the Women's Ischemia Syndrome Evaluation. *Circ Cardiovasc Imaging*. 2015;8(4). pii: e002481. doi:10.1161/CIRCIMAGING.114.002481.
47. Liu A, Wijesurendra RS, Liu JM, Forfar JC, Channon KM, Jerosch-Herold M, Piechnik SK, Neubauer S, Kharbanda RK, Ferreira VM. Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance. *J Am Coll Cardiol*. 2018;**71**:969-979.
48. Maseri A, Crea F, Kaski JC, Crake T. Mechanisms of angina pectoris in syndrome X. *J Am Coll Cardiol*. 1991;**17**:499-506.
49. Nihoyannopoulos P, Kaski JC, Crake T, Maseri A. Absence of myocardial dysfunction during stress in patients with syndrome X. *J Am Coll Cardiol* 1991;**18**:1463-1470.
50. Sicari R, Palinkas A, Pasanisi EG, Venneri L, Picano E. Long-term survival of patients with chest pain syndrome and angiographically normal or near-normal coronary arteries: the additional prognostic value of dipyridamole echocardiography test (DET). *Eur Heart J*. 2005;**26**:2136-2141.
51. Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Picano E, Sicari R. Prognostic value of Doppler echocardiographic-derived coronary flow velocity reserve of left anterior descending artery in octogenarians with stress echocardiography negative for wall motion criteria. *Eur Heart J Cardiovasc Imaging*. 2015;**16**:653-660.
52. Stegehuis VE, Wijntjens GW, Piek JJ, van de Hoef TP. Fractional flow reserve or coronary flow reserve for the assessment of myocardial perfusion : implications of FFR as an imperfect reference standard for myocardial ischemia. *Curr Cardiol Rep*. 2018;20:77.doi: 10.1007/s11886-018-1017-4.
53. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, Hill S, Schäufole T, Mahrholdt H, Kaski JC, Sechtem U. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. *Circulation*. 2014;129:1723-30.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
54. Cortell A, Marcos-Alberca P, Almería C, Rodrigo JL, Pérez-Isla L, Macaya C, Zamorano JL. Ergonovine stress echocardiography: Recent experience and safety in our centre. *World J Cardiol.* 2010;**2**:437-442.
55. Suzuki Y, Tokunaga S, Ikeguchi S, Niki S, Iwase T, Tomita T, Murakami T, Kawai C. Induction of coronary artery spasm by intracoronary acetylcholine: comparison with intracoronary ergonovine. *Am Heart J.* 1992;**124**:39-47.
56. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Bairey Merz CN; Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for vasospastic angina. *Eur Heart J.* 2017;**38**:2565-2568.
57. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). *Circ J.* 2014;**78**:2779-2801.
58. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC, Bairey Merz CN; Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol.* 2018;**250**:16-20.
59. Niccoli G, Scalone G, Crea F. Coronary functional tests in the catheterization laboratory - pathophysiological and clinical relevance. *Circ J.* 2015;**79**:676-684.
60. Lee JM, Hwang D, Park J, Zhang J, Tong Y, Kim CH, Bang JI, Suh M, Paeng JC, Cheon GJ, Koo BK. Exploring coronary circulatory response to stenosis and its association with invasive physiologic indexes using absolute myocardial blood flow and coronary pressure. *Circulation.* 2017;**136**:1798-1808.
61. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaikat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sidik N, McCartney P, Corcoran D, Collison D, Rush C, McConnachie A, Touyz RM, Oldroyd KG, Berry C. Stratified medical therapy using invasive coronary function testing in angina: cormica trial. *J Am Coll Cardiol.* 2018 Sep 19. pii:S0735-1097(18)38381-5. doi: 10.1016/j.jacc.2018.09.006. [Epub ahead of print].

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
62. ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHAEMIA) trial: Rationale and design. *Am Heart J.* 2018;**201**:124-135.
63. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. *Circulation.* 2010;**121**:2317-2325.
64. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. *Circulation.* 2011;**124**:1774-1782.
65. Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Sarullo FM, Lanza GA, Crea F. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. *Am J Cardiol.* 2013;**112**:8-13.
66. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. *N Engl J Med.* 1991;**325**:1551-1556.
67. Crea F, Lanza GA. Treatment of microvascular angina: the need for precision medicine. *Eur Heart J.* 2016;**37**:1514-1516.
68. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group . 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J.* 2018 Aug 25. doi: 10.1093/eurheartj/ehy394. [Epub ahead of print]

Legends to figures

Figure 1

Structural and functional alterations of coronary circulation responsible for persistence or recurrence of angina after percutaneous coronary intervention.

Figure 2

Top panels: Epicardial coronary spasm: representative images of a 55 year old male patient with several previous stent implantations in the right coronary artery (RCA) (red lines). The patient reported recurrent resting angina and underwent invasive coronary angiography. The RCA showed mild in-stent-proliferation. Intracoronary acetylcholine (A-Ch) testing revealed spasm of the RCA distal to the stents at 80 μ g with reproduction of the reported symptoms (A). After intracoronary nitroglycerine injection (400 μ g) the spasm and the symptoms resolved (B).

Bottom panels: Coronary microvascular spasm: representative images of a 64 year old female patient with previous stent implantation in the left anterior descending artery (LAD) (red lines). The patient reported recurrent angina at rest as well as during exertion and underwent invasive coronary angiography. The LAD showed mild in-stent-proliferation. Intracoronary acetylcholine testing revealed no epicardial spasm at 200 μ g, but reproduction of the reported symptoms together with ischemic ECG shifts on the simultaneously recorded 12-lead ECG (C). After intracoronary nitroglycerine injection (200 μ g) the ischemic ECG changes and the symptoms resolved (D).

Figure 3

A full investigation of the mechanisms of persistence or recurrence of angina after percutaneous coronary intervention in the catheterization laboratory should include the assessment of both structural and functional alterations of epicardial coronary arteries and of coronary microcirculation.

A-Ch = acetyl-choline; CFR= coronary flow reserve; IVUS = intravascular ultrasounds; OCT = optical coherence tomography.


Figure 4

Diagnostic flow chart in patients with persistent or recurrent angina after PCI. Colour coding: symptoms in yellow, diagnostic tools in purple, diagnostic findings in green and therapeutic recommendations in red.

A-Ch = acetylcholine, CFR = coronary flow reserve; Ergo = ergonovine maleate; FFR = fractional flow reserve; NHPR = non-hyperaemic pressure ratio; IMR = index of microvascular resistance; RWMA = regional wall motion abnormalities.


Table 1. Cause of persistence or recurrence of angina post-PCI

Mechanisms	Diagnostic criteria
<i>Flow limiting epicardial obstructions</i>	
Stent failure	
In-stent restenosis	Presence of $\geq 70\%$ stenosis in the stented segment and within 5 mm of stent edges at coronary angiography. Intermediate lesions should be interrogated with FFR.
Stent thrombosis (definite)	Presence of intracoronary thrombus that originates in the stent or segment 5 mm proximal or distal to the stent and presence of at least 1 of the following within a 48-hour time window: <ul style="list-style-type: none"> • Acute onset of ischaemic symptoms at rest • New ischaemic ECG changes that suggest acute ischemia • Typical rise and fall in cardiac biomarkers
CAD progression	Progression of coronary atherosclerosis in coronary segments different from those treated with index PCI, with presence of $\geq 70\%$ stenosis at coronary angiography. Intermediate lesions (40-70% diameter stenosis) should be interrogated with FFR.
Incomplete revascularisation	Residual stenosis of $\geq 50\%$ in the left main coronary artery or $\geq 70\%$ in another major epicardial coronary artery after index PCI. Intermediate lesions (40-70% stenosis) should be interrogated with FFR.
Diffuse coronary atherosclerosis	Diffuse coronary atherosclerosis at coronary angiography without angiographically significant stenosis, determining myocardial ischaemia as documented by reduced FFR (≤ 0.80).
Myocardial bridge	Disclosure at coronary angiography of a systolic narrowing, or “milking” of the vessel, with a “step-down” and “step-up” demarcating the affected area, and complete or partial decompression in diastole. Diastolic FFR with dobutamine challenge is a more appropriate approach for testing the haemodynamic significance of myocardial bridges.
Spontaneous coronary artery dissection (SCAD)	SCAD is defined as a separation within the arterial wall by intramural hematoma, which can occur by an intimal rupture initiating medial dissection or more commonly by a spontaneous intramedial haemorrhage resulting from disruption of the vasa vasorum
<i>Coronary vasomotion disorders of epicardial arteries and microcirculation</i>	
Epicardial spasm	Presence of focal or diffuse epicardial coronary diameter reduction $\geq 90\%$ during intracoronary ACh or ergonovine administration in comparison with the relaxed state following intracoronary nitroglycerin given to relieve the spasm, associated with reproduction of symptoms and ischaemic ECG shifts.
Microvascular spasm	Typical ischaemic ST-segment changes and angina developed during intracoronary ACh or ergonovine administration in the absence of epicardial coronary constriction $\geq 90\%$ diameter reduction.
Impaired coronary microvascular dilation	Reduction of coronary flow reserve (CFR $< 2.0-2.5$) in the absence of obstructive epicardial stenoses. Increase in the index of microvascular resistance (> 25) or the hyperaemic myocardial resistance (HMR ≥ 2 mmHg/cm/s)




STRUCTURAL


FUNCTIONAL




RESIDUAL DISEASE or DISEASE PROGRESSION




IN-STENT RESTENOSIS IN-STENT THROMBOSIS



DIFFUSE ATHEROSCLEROSIS




INTRAMYOCARDIAL BRIDGE



CORONARY DISSECTION





EPICARDIAL CORONARY ARTERY SPASM **MICROVASCULAR DYSFUNCTION**



UP TO 20-40% OF PATIENTS PRESENT ANGINA AFTER SUCCESSFUL PCI AT 1-YEAR FOLLOW UP





Figure



DISEASE PROGRESSION OR RESIDUAL DISEASE

YES

NO








PRESSURE WIRE
(To assess intermediate stenoses)


OCT/IVUS
(To exclude subcritical unstable plaque)

A-Ch or ERGONOVINE
(To test for epicardial or microvascular spasm)

DOPPLER WIRE
(To measure CFR and microvascular resistance)



Figure



Word count: 3472

No permission needed

Abstract

Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect up to 20-40% of patients at 1-year follow up. This appears to be true even when PCI is “optimised” using physiology-guided approaches and drug-eluting stents. Importantly, persistent or recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be almost 2-fold higher among patients with persistent or recurrent angina post-PCI versus those who become symptom-free. However, practice guideline recommendations regarding the management of patients with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina are relevant, and more research seems warranted. The purpose of this document is to review potential mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic algorithm and summarize current knowledge gaps.



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Bairey.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Beltrame.pdf





Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Berry.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Camici.pdf





Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)


COI Crea.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Kaski.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Ong.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Pepine.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Sechtem.pdf



Click here to access/download

ICMJE Conflicts of Interest form (1 for each author listed)

COI Shimokawa.pdf

